Mirum Pharmaceuticals Initiates Phase 3 Clinical Trial of Maralixibat for Pediatric Patients with Progressive Familial Intrahepatic Cholestasis

FOSTER CITY, Calif., July 9, 2019 /PRNewswire/ -- Mirum Pharmaceuticals today announced the dosing of the first patient in the Phase 3 MARCH-PFIC clinical trial of its lead drug candidate, maralixibat, in pediatric patients with...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials